Visiongain Reports on Inflammatory Bowel Disease Market Trends from 2016-2026

A new report by Visiongain predicts how high sales can go, to 2026, revealing medicines and years with highest predicted growth and revenues. Treating large-intestine disease holds much commercial potential. Explore what the future holds for treating inflamed bowel.
According to the news release:

R&D and other trends influencing those therapies and their producers
Our new analysis explains policies, issues and R&D shaping the IBD drugs industry and market. Assess the effects of these influences:
• IBD diagnosis, incidence and prevalence – see prospects for rising sales
• Monoclonal antibodies (mAbs) and biosimilars (follow-on protein products) – assess their potentials for changing that GI drugs market
• Drug delivery systems – advances in supporting technology
• Competition from generic drugs – see how they can erode that market
• Economic pressures – budgetary limitations in healthcare and therapy costs.
In particular our study discusses research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists.

Click here to view the full press release.